[Form 4] MiNK Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Brian Corvese, a director of MiNK Therapeutics, Inc. (INKT), was granted 1,290 restricted stock units (RSUs) on 09/02/2025 as board and committee compensation in lieu of cash. Each RSU represents a contingent right to receive one share of common stock and the grant price shown on the form is $13.86 per share. After the grant, the reporting person beneficially owns 48,441 shares. The RSUs are scheduled to vest one month from the grant date. The Form 4 was signed by an attorney-in-fact on 09/03/2025.

Positive

• Equity-based compensation aligns the director's interests with shareholders by tying pay to stock performance
• Non-cash award preserves company cash since RSUs were granted in lieu of cash retainers

Negative

• Potential dilution from RSU settlement when shares are issued, although the filing does not state the percentage impact

Insights

Corporate Governance Expert

TL;DR: Routine director compensation via RSUs aligns pay with shareholder interests and avoids immediate cash payouts.

The grant of 1,290 RSUs to a director as board and committee compensation is a common governance practice that ties director pay to company equity performance. Because the award was issued in lieu of cash retainers and vests after one month, it creates near-term alignment with shareholders while limiting immediate dilution. The reported beneficial ownership of 48,441 shares provides context for the director's existing stake, but the filing does not disclose the company’s total outstanding shares, so the percentage ownership impact cannot be calculated from this form alone.

Securities Analyst

TL;DR: This is a routine disclosure of a small equity grant; it is not a material corporate event.

The Form 4 reports a non-derivative acquisition of 1,290 RSUs at a per-share reference amount of $13.86, increasing the reporting person’s beneficial holdings to 48,441 shares. The transaction reflects compensation, not a market purchase or sale, and vests in one month, suggesting limited timing risk. There is no information here about other insider transactions, open-market trading plans, or total share count, so broader market or valuation implications cannot be determined from this filing alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corvese Brian

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		A		1,290	A	$13.86(1)	48,441	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

	By: /s/ Christine Klaskin, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MiNK Therapeutics insider Brian Corvese receive on 09/02/2025?

The Form 4 reports a grant of 1,290 RSUs, each convertible into one share of common stock, received in lieu of cash retainers.

How many shares does Brian Corvese beneficially own after the RSU grant?

After the reported transaction the reporting person beneficially owns 48,441 shares.

When do the RSUs granted to the director vest?

The RSUs are scheduled to vest one month from the grant date (granted 09/02/2025).

What price is listed on the Form 4 for the RSU grant?

The Form 4 shows a reference price of $13.86 per share for the reported RSU award.

Who signed the Form 4 and when was it filed?

The form was signed by an attorney-in-fact (/s/ Christine Klaskin) on 09/03/2025.